Sugi Predict

Sugi Predict / Compounds / SCHEMBL164631

SCHEMBL164631

SCHEMBL164631

CSc1nc(Cl)c(C=O)c(Cl)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.50
▸ CA2 P00918 5/20 0.50
▸ CA7 P43166 5/20 0.50
▸ CA13 Q8N1Q1 4/20 0.47
▸ MAPT P10636 5/20 0.33
▸ LMNA P02545 4/20 0.33
▸ KMT2A Q03164 3/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ NPSR1 Q6W5P4 2/20 0.33
▸ RECQL P46063 2/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ L3MBTL1 Q9Y468 4/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ SMN1; SMN2 Q16637 3/20 0.31
▸ HTT P42858 2/20 0.31
▸ HSP90AB1 P08238 1/20 0.31
▸ TP53 P04637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13431148 0.88 CA1 (0.46) CA1CA2CA7CA13MAPT
SCHEMBL13764860 0.86 CA1 (0.45) CA1CA2CA7CA13KMT2A
SCHEMBL1062911 0.86 CA1 (0.48) CA1CA2CA7CA13LMNA
SCHEMBL13283450 0.86 CA1 (0.45) CA1CA2CA7CA13
SCHEMBL25207733 0.83 CA1 (0.56) CA1CA2CA7CA13MAPT
SCHEMBL30924263 0.83 CA1 (0.56) CA1CA2CA7CA13MAPT
SCHEMBL14317409 0.79 CA1 (0.41) CA1CA2CA7CA13PPARG
SCHEMBL1060590 0.79 CA1 (0.52) CA1CA2CA7CA13MAPT
SCHEMBL13408212 0.79 CA1 (0.38) CA1CA2CA7CA13KMT2A
SCHEMBL30547237 0.78 CA1 (0.40) CA1CA2CA7CA13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4694980-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 Takeda Pharmaceutical Company Limited (JP) 2026-02-18 — — EP disclosed
US-12318388-B2 Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling Université de Liège (BE) 2025-06-03 — — US disclosed
US-20250152591-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS KURA ONCOLOGY INC (US) 2025-05-15 — — US disclosed
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A/ SK LIFE SCIENCE LABS 2025-04-10 — — US disclosed
WO-2025049994-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF ONCOPIA THERAPEUTICS, INC. D/B/A SK LIFE SCIENCE LABS (US) 2025-03-06 — — WO disclosed
WO-2025049619-A1 KRAS MODULATORS AND USES THEREOF QUANTA THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
EP-4472637-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS Kura Oncology, Inc. (US) 2024-12-11 — — EP disclosed
CN-115724844-B Heterocyclic compound with antitumor activity and application thereof 石药集团中奇制药技术（石家庄）有限公司 2024-10-18 — — CN disclosed
WO-2024214046-A1 PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2024-10-17 — — WO disclosed
CN-113329753-B Pyrimidine derivatives for the prevention and treatment of gram-negative bacterial infections, pollution and fouling 列日大学 2024-08-13 — — CN disclosed
EP-1406875-A4 N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION BRISTOL MYERS SQUIBB CO (US) 2005-05-04 — — EP disclosed
EP-1499320-A1 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2005-01-26 — — EP disclosed
US-20040209901-A1 Novel compounds SMITHKLINE BEECHAM CORPORATION 2004-10-21 — — US disclosed
US-20040116697-A1 Novel compounds GLAXOSMITHKLINE LLC 2004-06-17 — — US disclosed
EP-1406875-A1 N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION Bristol-Myers Squibb Company (US) 2004-04-14 — — EP disclosed
WO-2003088972-A1 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2003-10-30 — — WO disclosed
EP-1333833-A2 NOVEL COMPOUNDS SmithKline Beecham Corporation (US) 2003-08-13 — — EP disclosed
US-20030139435-A1 N-heterocyclic inhibitors of TNF-alpha expression BRISTOL-MYERS SQUIBB COMPANY 2003-07-24 — — US disclosed
WO-2003002544-A1 N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION BRISTOL-MYERS SQUIBB COMPANY (US) 2003-01-09 — — WO disclosed
WO-2002059083-A2 NOVEL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2002-08-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030139435-A1 N-heterocyclic inhibitors of TNF-alpha expression TNF, NFKBIA, TNFRSF1A CA1 2165/4885CA2 3441/4885CA7 3527/4885
US-20250152591-A1 TREATMENT OF HEMATOLOGICAL MALIGNANCIES WITH MENIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS MEN1, ABCB1, ABCC1 CA1 4491/4885CA2 3824/4885CA7 3828/4885
US-12318388-B2 Pyrimidine derivatives for prevention and treatment of gram-negative bacterial infection, contamination and fouling PIGS, TYMP, TYMS CA1 4266/4885CA2 3816/4885CA7 4207/4885
US-20250114345-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF EP300, CREBBP, HDAC1 CA1 3319/4885CA2 3229/4885CA7 2048/4885
US-20040209901-A1 Novel compounds MAPKAPK2, MAPKAPK3, MAPK7 CA1 4639/4885CA2 3740/4885CA7 3898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.